Loading stock data…
BAYN.DE
€37.08+0.10 (+0.27%)
Market ClosedLast close May 11
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Bayer Aktiengesellschaft in the Healthcare sector is trading at €37.08. The stock is currently 26% below its 52-week high of €49.78, remaining 8.2% above its 200-day moving average. Technical signals show oversold RSI of 30 and bearish MACD signal, explaining why BAYN.DE maintains its current momentum and trend strength. The Whystock Score of 70/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Oversold momentum (RSI 30) — potential for technical mean-reversion
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price€37.08
Potential Upside
5%
Whystock Fair Value€38.93
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus19 analysts
Buy
Mean target€48.47+30.7%
Range€25.00 – €60.00
Fundamentals
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
€39.61B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.89
Div Yield
Strong income play. Yield provides a meaningful total return floor.
27.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-12.37%
Volume
Today's trading volume
1.82M
Recent News
RXRX Q1 Loss Narrower Than Expected, Revenues Decline Y/Y
Recursion Pharmaceuticals reports a narrower-than-expected Q1 loss, but revenues fall sharply as Roche collaboration income declines year over year.
CYTK Q1 Earnings Match Estimates, Revenues Beat on Myqorzo Launch
Cytokinetics posts Q1 loss as Myqorzo launch lifts revenues to $19.4M, signaling commercial shift amid rising SG&A tied to rollout and expansion.
Bayer looks to uphold Eylea legacy with $2.45bn Perfuse buyout
If approved, the deal’s centrepiece, PER-001, could continue Bayer’s ophthalmology legacy defined by blockbuster retinal disease therapy, Eylea.
Bayer to buy Perfuse for up to $2.45B, bolstering eye drug pipeline
Centered around a glaucoma therapy in mid-stage testing, the deal is Bayer’s first drug company acquisition in several years and potentially its largest since it purchased AskBio in 2020.
Bayer acquiring Perfuse Therapeutics for up to $2.45 billion
Bayer will pay $300 million upfront, with the remainder tied to development, regulatory, and commercial milestones